Inventor · disambiguated record
Maj Hedtjärn
Also filed as: HEDTJAERN MAJ · HEDTJARN MAJ · HEDTJÄRN MAJ
18 granted patents·5 pending applications·114 citations·filing 2008–2023
94Inventor score
Files withROCHE INNOVATION CT COPENHAGEN AS12HEDTJARN MAJ3HOFFMANN LA ROCHE3ENZON PHARMACEUTICALS INC2HANSEN JENS BO RODE1
Top patents by PatentIndex Score
23 records- 0195US12259380B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2023·Granted Mar 25, 2025·2 cites·26 claims
- 0295US11852627B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2022·Granted Dec 26, 2023·3 cites·11 claims
- 0394US11320421B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2020·Granted May 3, 2022·3 cites·16 claims
- 0494US10739332B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 11, 2020·6 cites·5 claims
- 0593US10718753B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Jul 21, 2020·5 cites·9 claims
- 0693US8580756B2Short oligomer antagonist compounds for the modulation of target mRNAHANSEN JENS BO RODE·Filed 2008·Granted Nov 12, 2013·52 cites·17 claims
- 0792US9879265B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Granted Jan 30, 2018·17 cites·34 claims
- 0890US10494633B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Dec 3, 2019·8 cites·24 claims
- 0987US12421516B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2023·Granted Sep 23, 2025·0 cites·26 claims
- 1087US7863437B2RNA antagonist compounds for the modulation of PIK3CA expressionENZON PHARMACEUTICALS INC·Filed 2008·Granted Jan 4, 2011·6 cites·5 claims
- 1182US8268793B2RNA antagonist compounds for the modulation of HER3HEDTJARN MAJ·Filed 2008·Granted Sep 18, 2012·6 cites·11 claims
- 1278US11739332B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Granted Aug 29, 2023·0 cites·21 claims
- 1378US10443058B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Oct 15, 2019·1 cites·10 claims
- 1478US10385342B2Methods of treatment using antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 20, 2019·1 cites·63 claims
- 1578US10370668B2Manufacture of antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 6, 2019·1 cites·45 claims
- 1675US11091764B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 17, 2021·0 cites·50 claims
- 1773US9725723B2Compositions and methods for modulation of FGFR3 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2013·Granted Aug 8, 2017·3 cites·14 claims
- 1852US8450291B2RNA antagonist compounds for the modulation of PIK3CA expressionHEDTJARN MAJ·Filed 2010·Granted May 28, 2013·0 cites·14 claims
- 1952US2011124709A1Rna antagonists targeting gli2ENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2046US2012295955A1Rna antagonist compounds for the modulation of her3HEDTJARN MAJ·Filed 2012·Application pending·0 cites
- 2144US2016130582A1Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereofROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Application pending·0 cites
- 2242US2015315595A1Compositions and Methods for Modulation of ATXN3 ExpressionSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2335US2010249219A1Short rna antagonist compounds for the modulation of hif-1alphaHEDTJAERN MAJ·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maj Hedtjärn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →